title: [Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors in 31 cases].
abstract: OBJECTIVE
  Brain metastases (BM) from hepatocellular carcinoma (HCC) are rare and are associated with a poor prognosis. The aim of this study was to analyze the clinical features and evaluate the prognostic factors of brain metastases from hepatocellular carcinoma.
  
  
  METHODS
  The clinical data of thirty-one patients with HCC and BM treated in the First Affiliated Hospital of Xinjiang Medical University between January 1998 and December 2013 were retrospectively reviewed. Univariate and multivariate survival analyses were performed to identify possible prognostic factors.
  
  
  RESULTS
  Thrity-one patients were diagnosed with BM from HCC, an incidence rate of 0.61%. The median age at diagnosis of brain metastases was 48.5 years. Twenty-six patients were male. The median interval from diagnosis of hepatocellular carcinoma to brain metastases was 14 months. The median survival after the diagnosis of BM was 10 weeks. Univariate analysis showed that treatment modality, number of brain lesions, Karnofsky performance score, recursive partitioning analysis (RPA) class, and Child-Pugh classification had a statistically significant impact on the survival. The multivariate analysis showed that the low RPA class and aggressive brain radiotherapy were positively associated with improved survival.
  
  
  CONCLUSIONS
  BM from HCC is rare and associated with an extremely poor prognosis. However, patients with a low RPA class may benefit from aggressive brain radiotherapy.
authors.affiliation: Tumor Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: R L
authors.initials: RL
authors.lastname: Zhang
authors.affiliation: Tumor Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Tumor Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Tumor Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: L
authors.initials: L
authors.lastname: Xiao
authors.affiliation: Tumor Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Y N
authors.initials: YN
authors.lastname: Sun
authors.affiliation: Tumor Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Tumor Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Y X
authors.initials: YX
authors.lastname: Bao
mesh_terms: D000704:Analysis of Variance; D001932:Brain Neoplasms / Q000556:secondary*; D006528:Carcinoma, Hepatocellular / Q000556:secondary*; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008113:Liver Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies